Link to CV.doc

4,635 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
4,635
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
11
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Link to CV.doc

  1. 1. Last Updated: 1/2/2007 CURRICULUM VITAE PERSONAL DATA Name: Norman L. Foster Birth Date: July 27, 1951 Place of Birth: Jacksonville, Illinois, U.S.A. EDUCATION, CERTIFICATES and LICENSURE Baccalaureate Degree: 1969 – 1973 BA Biology & Chemistry, summa cum laude, MacMurray College, Jacksonville, IL Advanced Degree: 1973 – 1977 MD Washington University School of Medicine, St. Louis, MO Postdoctoral Training: 1981 – 1984 Fellow Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, MD 1978 – 1981 Resident Department of Neurology, University of Utah Hospitals, Salt Lake City, UT 1977 – 1978 Intern Straight Medicine, Jewish Hospital of St. Louis, Washington University Medical Center, St. Louis, MO Licenses/Certifications: 2005 – present State Medical License, Utah (#163537-1205, #163537-8905) 1984 – present State Medical License, Michigan (#4301047175) 1983 – present Neurology Diplomate, American Board of Neurology & Psychiatry 1979 (inactive) State Medical License, Utah (#6092) PROFESSIONAL EXPERIENCE Full-Time Positions 8/2005 – present Director, Center for Alzheimer’s Care, Imaging & Research, University of Utah, Salt Lake City, UT 8/2005 – present Professor, Department of Neurology, University of Utah, Salt Lake City, UT 8/2005 – present Senior Investigator, The Brain Institute, University of Utah, Salt Lake City, UT 8/2005 – present Adjunct Professor, Department of Neurology, University of Michigan, Ann Arbor, MI 9/2003 – 8/2005 Research Professor, Institute of Gerontology, University of Michigan, Ann Arbor, MI 9/1998 – 8/2005 Professor, Department of Neurology, University of Michigan, Ann Arbor, MI 7/1984 – 2005 Attending Staff Physician, University Hospital, University of Michigan, Ann Arbor, MI 9/1998 – 8/2003 Senior Research Scientist, Institute of Gerontology, University of Michigan, Ann Arbor, MI 7/1985 – 8/2002 Consultant and Attending Physician, Veterans Administration Hospital, Ann Arbor, MI 7/1984 – 8/1991 Assistant Professor, Department of Neurology, University of Michigan, Ann Arbor, MI 9/1997 – 8/1998 Senior Associate Research Scientist, Institute of Gerontology, University of Michigan, Ann Arbor, MI 9/1995 – 8/1997 Associate Research Scientist, Institute of Gerontology, University of Michigan, Ann Arbor, MI 9/1991 – 8/1998 Associate Professor, Department of Neurology, University of Michigan, Ann Arbor, MI 7/1983 – 6/1984 Attending Physician, Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, MD 7/1977 – 6/1978 Assistant in Medicine, Washington University, St. Louis, MO EDITORIAL EXPERIENCE Periodical Reviews Alzheimer Disease and Associated Disorders: 2002 American Journal of Geriatric Psychiatry: 2004, 2006 American Journal of Managed Care: 2003
  2. 2. Annals of Neurology: 1986 – 2003 Archives of Neurology: 1998 – 2006 Brain: 2004 – 2006 Clinical Neuropharmacology: 2005 European Journal of Neurology: 2004 Expert Review of Neurotherapeutics: 2003 Human Brain Mapping: 2005 Journal of Geriatric Psychiatry and Neurology: 1997 – present Journal of Gerontology, Part B Psychological Science and Social Science: 2000 Journal of Neuroophthamalogy: 2005 Journal of the American Geriatrics Society: 1985, 1995 – 2000 Journal of the Neurological Sciences: 1998 – 2000, 2002 – 2005 Neurobiology of Aging: 1983, 2004 Neuroimage: 2003 Neurology: 1987 – 2002, 2004 New England Journal of Medicine: 2000, 2005 Nicotine and Tobacco Research: 2002 Psychiatry Research Neuroimaging: 2003 Scandinavian Journal of Gastroenterology: 2002 Sleep: 2001 Telemedicine Journal and Electronic Health: 2002 The Clinical Neuropsychologist: 1990 Book Reviews Neurosurgery: 16:119, 1985 RESEARCH AWARDS Current Research Support Dates of Support Grant Information and Sponsor Role 11/1/06 -- 10/31/07 Early Detection of Alzheimer’s Disease in a Community Population P.I. Using Longitudinal Cognitive Assessment (Early AD Detection). Anonymous Foundation. 7/1/06 -- 6/30/10 Comprehensive Program to Strengthen Physician’s Training in Co-Investigator Geriatrics. Donald W. Reynolds Foundation. (PI: Supiano) 10/1/04 – 8/31/09 Alzheimer’s Disease Neuroimaging Initiative (ADNI) (U01 AG024904). P.I. NIA. 7/1/03 – 7/31/06 Pilot Collaborative PET Imaging Trial (R01-AG022394). NIA. P.I. 7/1/02 – 6/30/07 Training Grant: Training in Clinical and Basic Neuroscience (T32- Co-Investigator NS07222). National Institutes of Health, NINDS. Pending Research Support Dates of Support Grant Information and Sponsor Role 7/1/07 -- 6/30/12 Ancillary Studies to the Alzheimer’s Disease Neuroimaging Initiative Co-Investigator (ADNI) (PA-04-158). NIH. (PI: Whitaker) Completed Research Support Dates of Support Grant Information and Sponsor Role 7/1/01 – 6/30/05 Alzheimer’s Disease Cooperative Study (U01-AG10483). NIA. P.I. 7/1/96 – 6/30/01 Grant Extension P.I. Subprojects: 7/1/01 – 8/31/02 NSAID Trial. P.I. 4/1/99 – 7/30/04 MCI Trial: A randomized, double-blind, placebo-controlled trial P.I. to evaluate the safety and efficacy of vitamin E and donepezil HCl (Aricept) to delay clinical progression from mild cognitive impairment (MCI) to Alzheimer’s disease (AD). 3/1/94 – 9/30/96 Haloperidol, Trazadone, and Behavior Management P.I.
  3. 3. Techniques in Alzheimer’s Disease Patients with Disruptive Agitated Behaviors: A Controlled Clinical Trial. 7/1/93 – 6/30/95 A Multicenter Evaluation of New Treatment Efficacy P.I. Instruments for AD Clinical Trials. 6/1/92 – 6/30/95 A Double-Blind, Placebo-Controlled Multicenter P.I. Study to Examine the Safety and Efficacy of Selegiline and alpha-Tocopherol in the Treatment of Alzheimer’s Disease. 1/1/91 – 9/30/96 Project 3: Alzheimer Disease Study Units. P.I. 7/1/01 – 6/30/05 Training Grant: Comprehensive Programs to Strengthen Physicians’ Co-Investigator Training to Geriatrics. The Donald W Reynolds Foundation. 4/1/01 – 3/31/06 Training Grant: Identifying Cases and Costs of Dementia in the US (K08- P.I. AG19180-01). NIH, Mentored Clinical Scientist Development Award. 10/1/00 – 6/30/03 Collaborative PET Imaging Study (extended). NIH Prime (University of P.I. Washington National Alzheimer’s Disease Coordinating Center). 7/1/00 – 6/30/03 Training Grant: Program for Collaborative Interprofessional Team Co-Investigator Education (CITE) at the University of Michigan. Robert Woods Johnson Foundation Grant. 5/1/00 – 4/30/05 Multidisciplinary Research Training in Aging (T32-AG00114). NIH. Co-Investigator 12/21/99 – A Multicenter Randomized Double-Blind, Placebo-Controlled Study to Co-Investigator 12/21/00 Evaluate AIT-082 in Patients with Probable Alzheimer’s Disease of Mild to Moderate Severity (90 day treatment period plus 60 day follow-up). NeoTherapeutics, Inc. and Synapse Technologies, Inc. 12/1/99 – 11/30/00 A 30 Week, Open-label Evaluation of Donepezil Hydrochloride (E2020) Co-Investigator in Patients with Dementia Associated with Cerebrovascular Disease (Protocol E2020-A001-309). Eisai, Inc. 7/1/99 – 5/31/00 Michigan Alzheimer Disease Research Center (P50-AG08671). NIA. P.I. Subprojects: 6/1/99 – 5/31/05 Core B, Clinical Core (with bridging funds). P.I. 6/1/94 – 5/31/99 Core B, Clinical Core. P.I. 6/1/94 – 5/31/99 Project 2: Neuropharmacologic Challenges in P.I. Dementia. 9/30/92 – 5/31/94 Administrative Supplement: Northern Michigan P.I. Satellite Diagnostic and Treatment Center. 7/1/91 – 5/31/94 Administrative Supplement: Detroit Satellite P.I. Diagnostic and Treatment Center. 10/1/89 – 9/30/94 Core A: Clinical Core. P.I. 10/1/89 – 9/30/94 Project 2: Neuropharmacologic Challenges in P.I. Dementia. 6/1/03 – 5/31/04 Depression/HPA Axis Dysregulation Increases Co-Investigator Alzheimer’s Risk in Mild Cognitive Impairment. 6/1/99 – 5/31/04 Core A: Administrative Core. Co-Investigator 6/1/94 – 5/31/99 Project 1: Benzodiazepine Receptors in Co-Investigator Neurodegenerative Disease. 6/1/94 – 5/31/99 Core A: Administrative Core. Co-Investigator 10/1/89 – 9/30/94 Project 1: Motor Correlates of Dementia. Co-Investigator 7/1/97 – 6/30/02 Training Grant: Training in Clinical and Basic Neuroscience (T32- Co-Investigator NS07222). NIH, NINDS. 7/1/97 – 5/30/01 ADCS Supplement: Vitamin E to Prevent Progression to AD. NIA. P.I. 7/1/97 – 6/30/00 Training Grant: Innovations in Health Professions Education. State of Co-Investigator Michigan, Department of Community Health. 1/2/97 – 5/31/98 An Open-label Study to Evaluate the Safety and Efficacy of 1.5mg b.i.d. Co-Investigator
  4. 4. (3mg/day) through 6mg b.i.d. (12mg/day) of Exelon in Patients with Mild to Severe Probable Alzheimer’s Disease in the Community Setting (Protocol ENAB-356). Novartis Pharmaceutical Corporation. 12/1/96 – 11/30/01 Emission Computed Tomography of Local Cerebral Function (R01- Co-Investigator NS20867). NIH, NINDS. 9/1/96 – 8/31/97 A Conference on Chromosome 17-linked Dementias (R13-AG13904). P.I. NIH. 7/1/96 – 3/31/99 Documenting the African-American Health Care Experience in Michigan P.I. (including 1 year no cost extension). WK Kellogg Foundation. 7/1/ 96 – 3/31/98 Grant Extension Co-Investigator 5/1/95 – 4/30/00 Training Grant: Multidisciplinary Research Training in Aging (T32- Co-Investigator AG00114). NIA. 9/1/95 – 8/31/97 Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) P.I. (U01-AG06790). NIA. 11/1/90 – 10/31/95 Grant Extension P.I. 6/1/95 – 12/31/97 A 52-Week, Randomized, Double-Blind, Placebo-Controlled Study of Co-Investigator Acetyl-L-Carnitine in Patients with Age-Defined (Between 45 and 65 Years of Age) Alzheimer’s Disease (ST-94-101). Quintiles Pacific, Inc. (Sigma Tau Gamma Pharmaceuticals). 6/1/95 – 12/31/97 A Multi-center, Double-Blind, Placebo-Controlled Study of Acetyl-L- Co-Investigator Carnitine in Patients with Age-Defined (Between 45 and 65 Years of Age) Alzheimer’s Disease (ST-94-101). Quintiles Pacific, Inc. (Sigma Tau Gamma Pharmaceuticals). 10/1/93 – 12/31/94 A Controlled Study of Ondansetron in the Treatment of Primary P.I. Degenerative Dementia of the Alzheimer Type, Protocol S3A-228. Glaxo Research Institute. 7/1/93 – 6/30/95 Behavioral Shaping for Disruptive Behavior in Dementia (F33-NR06911). P.I. NIH, Senior National Research Service Award. 7/1/92 – 10/1/93 The Cognex Treatment IND Program for Patients with Alzheimer’s P.I. Disease (970-58). Warner-Lambert/Parke-Davis Pharmaceutical Research Division. 1/1/92 – 12/31/94 A Double-Blind, Placebo-Controlled, Safety, Tolerability and Efficacy P.I. Study of L-693 487 (heptylphysostigmine) following Slow Titration in Patients with Alzheimer’s Disease. Merck Sharp and Dohme Pharmaceutical Company. 11/1/91 – 12/31/94 Open-Label Extension of Protocol 970-61 (protocol 970-62). Warner- P.I. Lambert/Parke-Davis Pharmaceutical Research Division. 11/1/91 – 12/31/94 A Double-blind, Placebo-controlled, Parallel Group, High-Dose Study of P.I. Tacrine (CI-970) in Patients with Alzheimer’s Disease (Protocol 970-61). Warner-Lambert/Parke-Davis Pharmaceutical Research Division. 4/1/91 – 5/31/93 Double-blind, Placebo-Controlled, Parallel Group Multi-center Study of P.I. Tacrine (CI-970) in Alzheimer’s Disease Patients (Protocol 970-26). Warner-Lambert/Parke-Davis Pharmaceutical Research Division. 9/1/90 – 4/30/93 Effect of Idebenone and Placebo on Regional Cerebral Glucose P.I. Metabolism and Neuropsychological Performance in Patients with Alzheimer’s Disease (M89-383). Takeda-Abbott Research and Development Company (later TAP Pharmaceuticals). 7/1/90 – 7/31/94 Neuropharmacologic Challenges in Dementia (R01-MH47144) (including P.I. 1 year no cost extension). NIH. 6/1/90 – 10/31/92 An Open-Label, Multicenter Safety Study of Tacrine Hydrochloride P.I. (CI-970) in Alzheimer’s Disease Patients with Prior Exposure to Tacrine in a Parke-Davis Sponsored Clinical Trial (Protocol 970-15-602). Warner-Lambert/Parke-Davis Pharmaceutical Research Division. 12/1/89 – 11/30/94 PET Study of Biochemistry and Metabolism of the CNS (P01-NS15655). Co-Investigator NIH, NINCDS.
  5. 5. 7/1/89 – 6/30/91 A Pilot Prospective Study of Magnetic Resonance Imaging and Positron Co-Investigator Emission Tomography in Lupus Patients with Dementia (CRC Project #835) (M01-RR00042). University of Michigan Clinical Research Center. 7/1/89 – 9/28/89 The Role of Glutamate in Alzheimer’s Disease (R01-AG06155). NIA. Co-Investigator Grant Extension: 4/1/86 – 3/31/89, Co-Investigator. 5/1/89 – 4/30/90 Neuropsychological Studies of Milacemide in the Treatment of Co-Investigator Alzheimer’s Disease. G D Searle and Company. 5/1/89 – 9/1/89 Milacemide in the Treatment of Alzheimer’s Disease (NC7-88-02-033). P.I. G D Searle and Company. 4/1/89 – 3/31/94 Emission Computed Tomography of Local Cerebral Function (R01- Co-Investigator NS20867). NIH, NINCDS. Grant Extension: 7/1/86 – 3/31/89, Co- Investigator. 9/1/88 – 8/31/90 The Ethel and James Flinn Family Foundation Grant. The Ethel and Co-Investigator James Flinn Family Foundation Grant. 8/10/88 – 12/31/92 A Double-Blind Placebo-Controlled Multicenter Study of Tacrine (CI-970) P.I. and Lecithin (CI-909) in Alzheimer’s Disease Patients. Warner-Lambert/ Parke-Davis Pharmaceutical Research Division. 1/1/88 – 12/31/88 SPECT and the Prognosis of Memory Loss (# 386136). Horace H P.I. Rackham Faculty Research Grant. 5/1/87 – 4/30/88 A Double-Blind, Placebo-Controlled Multicenter Study of CI-933 in Age- Co-Investigator Associated Memory Impairment. Warner-Lambert/Parke-Davis Company. 2/1/87 – 7/1/89 Cholinergic Agonist RS-86 in Progressive Supranuclear Palsy (CRC P.I. Project #670) (M01-RR00042). University of Michigan Clinical Research Center. 8/1/86 – 8/1/87 A Placebo-Controlled Compassionate Plea Study of Pramiracetam in an P.I. Alzheimer Patient (Warner-Lambert Protocol #879-34). Warner-Lambert/ Parke-Davis Pharmaceutical Research Division. 2/1/86 – 6/30/90 PET Investigations of Alzheimer’s Disease (CRC Project #572) (M01- P.I. RR00042). University of Michigan Clinical Research Center. 7/1/85 – 6/30/90 PET Investigations of Alzheimer’s Disease (K08-NS-01023). National P.I. Institute of Neurologic Disorders and Stroke. **PET Operating Committee, PET Pilot Project. 7/1/85 – 11/30/89 PET Study of Biochemistry and Metabolism of CNS, Subproject: PET P.I. Investigations of Alzheimer’s Disease (P01-NS-15655-06S1). National Institute of Neurologic Disorders and Stroke. 12/1/84 – 11/30/89 PET Study of Biochemistry and Metabolism of the CNS (P01-NS15655). Co-Investigator NIH, NINCDS. Training Grant: “A Randomized, Double-Blind, Placebo-Controlled Co-Investigator Evaluation of the Safety and Efficacy of Memantine in Patients with Mild to Moderate Dementia of the Alzheimer’s Type (MEM-MD-10)”, Forest Pharmaceuticals SCHOLASTIC HONORS and AWARDS 1996 – 2004 Listed in “The Best Doctors in America” 2000, 2004 Listed in “Detroit’s Top Docs” for Alzheimer’s Disease, Metropolitan Detroit Monthly Hour Magazine 1996 – 1997 Listed in “The Best Doctors in America: Midwest Region” 1995 Doctor of Science (Honorary), MacMurray College 1985 - 1990 Clinical Investigator Development Award, NIH 1983 Young Alumnus of the Year, MacMurray College 1977 Alpha Omega Alpha 1977 Upjohn Achievement Award
  6. 6. ADMINISTRATIVE EXPERIENCE Administrative Duties 2006 - present Medical Director, Cognitive Disorders Clinic, Center for Alzheimer’s Care, Imaging and Research, Department of Neurology, University of Utah 2005 - present Director, Center for Alzheimer’s Care, Imaging and Research, Department of Neurology, University of Utah 1994 – 2004 Associate Director, Michigan Alzheimer’s Disease Research Center 1989 – 2005 Director, Clinical Core, Michigan Alzheimer’s Disease Research Center 1984 – 2005 Director, Cognitive Disorders Clinic, Department of Neurology Professional & Scientific Committees International: Sep 2006 -- Member, Geriatric Research Education and Clinical Center (GRECC) Advisory Committee, Department of Veterans Affairs Medical Center (Salt Lake City, UT) 2004 Scientific Committee Member, 2004 Alzheimer’s Imaging Consortium, pre- conference to the International Conference on Alzheimer’s Disease, Philadelphia, PA National: 2004, 2006 Panel of Judges, Alzheimer’s Disease Neuroimaging Award, Alzheimer’s Association 2005 – present Scientific Advisory Board, Myriad Pharmaceuticals (Salt Lake City, UT). 2005 – present External Advisory Committee, Alzheimer’s Disease Research Center, University of Alabama (Birmingham, AL). 2003 – present Executive Committee Member, Geriatric Neurology Section, American Academy of Neurology 2002 – 2005 Executive Committee Member (elected position), Clinical Core Directors of Alzheimer Disease Centers, NIA 2002 – 2003 Clinical Task Force Member, Alzheimer Disease Centers, NIA 2002 PET Advisory Panel Member, NIH/NIA Neuroimaging Initiative 2001 – 2003 Neuroimaging Workgroup Member, The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging 1999 – 2003 Practice Committee Member, Geriatric Neurology Section, American Academy of Neurology 1999 – present Clinical Practice Committee Member, Geriatric Neurology Section, American Academy of Neurology 1997 Member of Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease”, The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association & National Institute on Aging 1997 Dementia Advisory Committee Member, Asset and Health Dynamics Study 1996 – 1997 Datasharing Committee Member, Alzheimer Disease Centers, NIA Dec 9, 1991 Research Panel, Virginia M. Cullen Memorial Alzheimer’s Education Seminar, St. Joseph Mercy Hospital (Pontiac, MI). Feb 4, 1991 Dementia Consensus Panel Member, Brain Imaging Council, Society of Nuclear Medicine (Tampa, FL). 1986 – 1987 President, American Society of Neurological Investigation 1985 – 1986 Secretary/Treasurer, American Society of Neurological Investigation Regional: 1997 – 1998 Assisted Living Task Force Member, Michigan Department of Consumer and Industry Services. 1997 – 1998 Screening Advisory Committee Member, Michigan Medicaid Long-term Managed Care Plan (MI-Choice), Michigan Department of Community Health. 1996 – 1997 Mental Health and Aging Advisory Committee, Michigan Department of Community Health. 1994 – 1999 Dementia Services Coordinating Committee Member, Michigan Public Health Institute. 1987 – 1994 Member of Subcommittee on the Dementias, Chronic Disease Advisory Committee, Michigan Department of Public Health.
  7. 7. 1987 Support Group Leaders, “Recent Research in Alzheimer’s Disease,” Alzheimer’s Disease and Related Disorders Association, Greater Ann Arbor Chapter (Ann Arbor, MI). 1986 – 2005 Physician Advisor, The Greater Washtenaw Area Tel-Med (Ann Arbor, MI). 1985 – 1992 Scientific Advisory Board Member, Alzheimer’s Disease and Related Disorders Association, Greater Ann Arbor Chapter (Ann Arbor, MI). 1985 Site Visit Team, Aging Review Committee, National Institute on Aging. Grant Review Committees, Study Sections 2004 Director’s Review Committee Member, Life Sciences Division, Ernest Orlando Lawrence Berkeley National Laboratory. Feb 21, 2003 Special Emphasis Panel Member, ZRG1-BDCN-1 (02), Brain Disorders and Clinical Neuroscience Initial Review Group, National Institutes of Health. 2003 Grant Reviewer, General Clinical Research Center, University of Michigan. 2000 – 2003 Abstract Reviewer, American Academy of Neurology Annual Meeting. Jun 10, 2002 Ad Hoc Reviewer, BDCN-1, Brain Disorders and Clinical Neuroscience-1 Study Section, National Institutes of Health. Oct 23-24, 2001 Special Emphasis Panel Member, Review of Mentored Clinical Scientist Development Awards in Alzheimer’s Disease and Related Dementias, NIA. 1997 – 2001 Initial Review Board Member, Medical and Scientific Advisory Council, Ronald and Nancy Reagan Research Institute, Alzheimer's Association. 1999 – 2000 Special Emphasis Panel Member, Review of Grants for Alzheimer’s Disease Pilot Clinical Trials, NIA. 1999 Reviewer, Alzheimer’s Disease Research Centers of California. 1989 Ad Hoc Reviewer, National Institute of Mental Health. 1989 Special Review Group Member, Human Development and Aging Study Section, National Institutes of Health. 1988 External Reviewer, Veterans Administration Merit Grants. 1987, 1989 Field Reader, Orphan Products Development Grants Program, FDA. 1986 Ad Hoc Reviewer, National Institute on Aging. 1985 - present Michigan Peer Review Organization. 1985, 1988 Ad Hoc Review Committee Member, Alzheimer’s Disease Research Centers, National Institute on Aging. 1985, 1986, 1987 Special Reviewer, Sensory Disorders and Language Study Section, National Institutes of Health. 1986 – present Member, Research Group on the Dementias, World Federation of Neurology 1983 Consultant Member, Orphan Products Development Initial Review Group, FDA. Meeting Chair or Coordinator International: Sep 7, 2006 Co-Chair, Behavior in FTLD, 5th International Conference on Frontotemporal Dementia (FTD) (San Francisco, CA) Jul 15, 2006 Co-Chair, Molecular Imaging Oral Session, Alzheimer’s Imaging Consortium, 10th International Conference on Alzheimer’s Disease (Madrid, Spain) Regional: Jun 17-18, 2006 Chair, Pilot Collaborative PET Imaging Trial, 3rd Expert Consensus Panel Meeting (Park City, UT) Jan 21-22, 2006 Chair, Pilot Collaborative PET Imaging Trial, 2nd Expert Consensus Panel Meeting (SLC, UT) April 1, 2003 Co-Chair, Session 18: “Aging and Dementia: Neuroimaging”, 55th Annual Meeting, American Academy of Neurology (Honolulu, HI) 2000 – 2001 Organizer, Monthly Clinical Conference, Michigan Alzheimer’s Disease Research Center (Ann Arbor, MI)
  8. 8. 1999 Organizer and Moderator, “Workshop on Dementia Training for Primary Care Physicians” 1999 Organizer and Moderator, “Neuropsychological Assessment of Dementia”, Michigan Union Oct 4-6, 1996 Organizer, “Conference on Chromosome 17-related Dementia” (Ann Arbor, MI) May 1992 Co-Chair, Session 58: “Aging and Dementia VI: Functional Neuroimaging”, 44th Annual Meeting, American Academy of Neurology (San Diego, CA) Apr 25, 1991 Co-Chair, “Aging and Dementia: Metabolism and Brain Imaging”, 43rd Annual Meeting, American Academy of Neurology (Boston, MA) May 2, 1990 Co-Chair, “Aging and Dementia: Brain Imaging and Epidemiology”, 42nd Annual Meeting of the American Academy of Neurology (Miami Beach, FL) 1986 Organizing Committee Member, 1st Meeting of Scientific Investigators in Michigan Study Alzheimer’s Disease and Related Disorders (Dearborn, MI) Oct 8, 1986 Organizer and Moderator, “The Future of Academic Neurology”, 6th Annual Meeting of the American Society for Neurological Investigators (Boston, MA) Apr 9, 1986 Organizing Committee, 1st Meeting of Scientific Investigators in Michigan Study Alzheimer’s Disease and Related Disorders (Dearborn, MI). PROFESSIONAL ACTIVITIES Membership in Professional Societies American Academy of Neurology, 1980-- Junior Member, 1980-1983 Active Member, 1983-1987 Fellow, 1987-- Member, Geriatric Neurology Section, 1996-- Clinical Practice Committee, 1999-- American Association for the Advancement of Science, 1985-- Section on Neurosciences Section on Medical Sciences Section on Societal Impacts of Science and Engineering American Neurological Association, 1992-- American Society for Neurological Investigation, 1981-1991 Secretary-Treasurer, 1985-1986 President, 1986-1987 International Neuropsychology Society, 1985-- International Society of Cerebral Blood Flow and Metabolism, 1988-- Michigan Neurological Association, 1984-- World Federation of Neurology Research Group on the Dementias, 1986-- SCIENTIFIC and PROFESSIONAL MEETINGS ATTENDED (without presentations) Dec 14, 2006 External Advisory Committee Meeting, University of Alabama (Birmingham, AL) Dec 6, 2006 Personalized Medicine in Utah Conference & Reception (SLC, UT) Oct 8-9, 2006 Alzheimer’s Disease Neuroimaging Initiative (ADNI) Fall Steering Committee Meeting (Chicago, IL) Sep 6-8, 2006 5th International Frontotemporal Dementia Conference (San Francisco, CA) Aug 9, 2006 Cache County Memory Study (CCMS) Research Retreat (Logan, UT) Jun 16-18, 2006 Pilot Collaborative PET Imaging Trial Expert Consensus Panel Meeting (Park City, UT) Apr 4, 2006 The American Academy of Neurology 58th Annual Meeting (San Diego, CA) Apr 3, 2006 Alzheimer’s Disease Neuroimaging Initiative (ADNI) Spring Steering Committee Meeting (San Diego, CA) Jan 21-22, 2006 Pilot Collaborative PET Imaging Trial Expert Consensus Panel Meeting (SLC, UT) Oct 24-25, 2005 University of Alabama Alzheimer’s Disease Research Center, External Advisory Committee Meeting (Birmingham, AL) Jul 17-22, 2004 The 9th International Conference on Alzheimer’s Disease and Related Disorders (Philadelphia, PA)
  9. 9. COMMUNITY ACTIVITIES Community Leadership 2005 – now Member, Utah State Commission on Aging (Salt Lake City, UT) 1986 – 2005 Physician Advisor, The Greater Washtenaw Area Tel-Med (Ann Arbor, MI) 1985 – 1992 Advisory Board, ADRDA, Greater Ann Arbor Chapter (Ann Arbor, MI) PUBLICITY and PRESS International: Mar 8, 2005 Interview (television): “Sporadic CJD”, The National, Canadian Broadcasting Corporation. Anita Mielewczyk, producer; Kelly Crowe, reporter; Randy Shedlowich, cameraman. Jan 20, 2005 Interview (telephone): “Sporadic CJD”, The National, Canadian Broadcasting Corporation, Prab Dhanoa. May 2, 2002 Interview: “Two Cases of Early Onset Sporadic Creutzfeldt-Jakob Disease in Michigan”, New Scientist (London, England), Deborah McKenzie National: Nov 5, 2004 Interview (telephone): “The Alzheimer’s Disease Neuroimaging Initiative and the Future of Imaging in Dementia”, Advance for Radiology, Joyce Ward. Oct 14, 2004 Interview (telephone): “The Role of PET in the Early Diagnosis of Alzheimer’s Disease”, Diagnostic Imaging, Chris Kaiser. Jan 14, 2004 Interview: “Advanced Planning for Dementia Care”, ADVANCE for Occupational Therapy Practitioners, a publication of Merion Advance newsmagazines, Jill Glomstad. Mar 25, 2003 Interview (telephone): “Comment on ‘Creutzfeldt-Jakob Disease in Deer and Elk Hunters’ by Murinova et al., Neurology 2003; 60:A190”, New Scientist, Anil Ananthaswamy. Oct 22, 2002 Interview (telephone): “PET Imaging in Alzheimer’s Disease”, Associated Press, Daniel Haney. Aug 27, 2002 Interview: “Two Cases of Prion Disease in Michigan”, The Todd Mundt Show, National Public Radio and WUOM, Todd Mundt. Broadcast and webcast 9/6-20/2002. Sep 2002 Interview: “Hypotension May Cause Frontotemporal Dementia”, Neurology Today, Kurt Samson. Published with portrait, pg. 35-6. May 15, 2002 Interview: “Two Cases of Early Onset Sporadic Creutzfeldt-Jakob Disease in Michigan”, Associated Press (Detroit, MI), Andrea Menzie. May 1, 2002 Interview: “Two Cases of Early Onset Sporadic Creutzfeldt-Jakob Disease in Michigan”, Wall Street Journal, Antonio Regalado. Apr 26, 2002 Interview: “Two Cases of Early Onset Sporadic Creutzfeldt-Jakob Disease in Michigan”, USA Today, Anita Manning. Appeared 4/29/2002. Apr 6, 2001 Interview: “Laboratory Testing in Alzheimer’s Disease”, Laboratory Advances, Pam Tarapchak. Excerpts published in “Shining Light into the Dark”, Advance for Administrators of the Laboratory 2001: 10 (7, Jul) 70-76. Jan 12, 2001 Interview: “Strategies for Preventing Alzheimer’s Disease”, CBS Healthwatch, Peter Downs. Regional: Nov 27, 2006 Live TV Appearance: Good Things Utah, Channel 4 ABC (Salt Lake City, UT) Nov 22, 2006 Interview: Lois Collins, Deseret News (Salt Lake City, UT) Nov 22, 2006 Live Radio Appearance: KCPW Mid-Day Metro (Salt Lake City, UT) Nov 10, 2006 Interview: Julie Roberts, ReDirect Marketing for the Brain Institute at the University of Utah (Salt Lake City, UT) Aug 29, 2006 Podcast Recording, Interviewer: Phil Sahm, University of Utah Public Relations Apr 2006 Featured: “Incidence of Alzheimer’s Disease on the Rise in Utah”, Utah Health Magazine. Nov 28, 2005 Interview: “Healing Memory: U Alzheimer’s Center to fill need for research and treatment”, Daily Utah Chronicle, The University of Utah, Morgan Ratcliffe.
  10. 10. Nov 21, 2005 Featured: “An Alzheimer’s Program for the 21st Century: Top Expert to Open Clinic at U of U, Join New Brain Institute”, University of Utah News and Public Relations Press Release, Phil Sahm. Nov 2005 Author, op-editorial: “New Hope for Alzheimer’s Disease”, The Salt Lake Tribune. Co-author: Michael Wood, President of the Board of Directors for the Utah Chapter of the Alzheimer’s Association. Nov 2005 Interview: KUER, KUEN Oct 28, 2004 Interview: “The Alzheimer’s Disease Neuroimaging Initiative”, Michigan Daily (Ann Arbor, MI), Genevieve Lampinen. Published Nov 2, 2004. Oct 15, 2004 Interview: “The Alzheimer’s Disease Neuroimaging Initiative”, WKZO AM 590 radio (Kalamazoo, MI), Jim O’Connell. Oct 13, 2004 Interview (taped): “The Alzheimer’s Disease Neuroimaging Initiative”, WUOM radio (Ann Arbor, MI), Tracy Similton. Oct 13, 2004 Interview (taped): “The Alzheimer’s Disease Neuroimaging Initiative”, WAAM radio (Ann Arbor, MI), Glen Law. Jun 29, 2004 Interview (telephone): “FDG-PET and Biomarkers in the Early Diagnosis of Alzheimer’s Disease”, Boston Globe, Alice Dembner. Appeared in the Tuesday Science Section, July 6, 2004. Feb 13, 2004 Interview: “Creutzfeldt-Jakob Disease in Michigan”, WXYZ TV, Channel 7, JoAnn Purtan. May 13, 2003 Interview: “African American Health Care in Detroit – the Legacy of Segregation”, WDET-FM (Detroit, MI), Craig Fahle. For a series to be aired in June 2003. Oct 4, 2002 Interview (videotaped): “PET Imaging in Alzheimer’s Disease”, Victor/Harder Productions of West Bloomfield Michigan, Fran Victor. Aug 14, 2002 Interview: “Likely Higher than Expected Occurrence of Prion Disease in Young People”, Connecticut Post (Bridgeport, CN), Marion Brown. Apr 30, 2002 Interview: “Two Cases of Early Onset Sporadic Creutzfeldt-Jakob Disease in Michigan”, Fox 2 Detroit, Bob Gallagher. Aired 4/30/02. Apr 26, 2002 Interview: “Two Cases of Early Onset Sporadic Creutzfeldt-Jakob Disease in Michigan”, The Rocky Mountain News (Denver, CO), Lou Kilzer. Aired 4/27/02. Oct 4, 2001 Interview: “Healthy Aging and Brain Function”, Michigan Talk Radio, Bob White. Sep 27, 2001 Interview: “Creutzfeldt-Jakob Disease in a Young Man from Port Huron”, Port Huron Times- Herald, Amber Hunt. Feb 21, 2001 Interview: “Update on Alzheimer’s Disease Research”, Traverse City, MI. Nov 10, 2000 Interview (one-hour radio interview and listener call-in): “Documenting the History of African- American Health Care in Southeast Michigan”, WAAM, the Ted Heusel Show (Ann Arbor, MI), John Bacon. Dec 7, 1999 Interview (videotaped): “Clinical Trial to Prevent Alzheimer’s Disease”, Ivanhoe Productions (Orlando, FL), Mary Zagar White. Nov 10, 1999 Interview (videotaped): “Clinical Trial to Prevent Alzheimer’s Disease”, MedStar TV Health News (Allentown, PA), Karen Zeitlin. Sep 1999 Interview (videotaped): “Clinical Trial to Prevent Alzheimer’s Disease”, Victor/Harder Productions (West Bloomfiel, MI), Fran Victor. Jun 10, 1997 Interview: “Alzheimer's Research and the Cancer-Geriatric Center at the University of Michigan”, Oakland Press, Julie Balunkel. Jun 3, 1997 Interview: “Vitamin E and Alzheimer's Disease”, Warren Pierce Radio network and WAAM, Warren Pierce. Apr 25, 1997 Interview (on-air): “Vitamin E and Alzheimer's Disease”, WAAM (Ann Arbor, MI), Dave Pekrul. Apr 24, 1997 Interview (on-air): “Vitamin E and Alzheimer's Disease”, WWJ (Detroit, MI). Apr 23, 1997 Interview: “Vitamin E and Alzheimer's Disease”, The Detroit News, Pat Amstett. Front-page story appeared Apr 24, 1997. Apr 23, 1997 Interview: “Vitamin E and Alzheimer's Disease”, WAAM (Ann Arbor, MI). Apr 23, 1997 Interview: “Vitamin E and Alzheimer's Disease”, WUOM (Ann Arbor, MI), Joan Silvie. Apr 15, 1997 Interview: “Familial Alzheimer's Disease”, WDIV Channel 4 Detroit, Delle Warner.
  11. 11. Oct 28, 1996 Interview: “New Brain Illness Mimics Alzheimer's”, The Detroit News, James Tobin. Oct 1996 Interview: “Health Update” (Chromosme 17 related Dementia Conference), WWJ. Oct 1, 1996 Interview on Chromosome 17-related Dementia, Channel 7 WXYZ Detroit, Jerry Hodak. Nov 8, 1994 Interview (on-air with audience call-in): “Ronald Reagan and Alzheimer’s Disease”, WXYT Detroit, David Newman. Oct 3, 1994 Interview (television): “Alzheimer’s Disease”, Channel 4 WDIV Detroit, Delle Warner. Aug 29, 1994 Interview (radio): “Alzheimer’s Disease Today”, WMPL (Houghton, MI), Mike Foster. Oct 19, 1993 Interview (radio): “Community Outreach Education Project: A Thumb Area Response”, WLEW (Bad Axe, MI), Craig Routzahm. Oct 19, 1993 Interview (radio): “Community Outreach Education Project: A Thumb Area Response”, WMIC (Sandusky, MI), Bob Armstrong. Mar 20, 1991 Interview: “THA, Alzheimer’s Disease and the FDA”, John Del-Monice Show, WAAM. Oct 29, 1987 Interview: “Alzheimer’s Disease Awareness Month”, Fred Hindley Show, WUOM. Nov 9, 1987 Interview: “Alzheimer’s Disease”, Ted Heusel Show, WAAM. Nov 19, 1986 Interview (radio): “Alzheimer’s Disease and THA”, J. P. McCarthy Show, WJR Detroit. Nov 13, 1986 Interview (on-air with audience call-in): “Alzheimer’s Disease Awareness Month”, Ted Heusel Show, WAAM (Ann Arbor, MI). Aug 8, 1985 Interview: “PET Scanning in Alzheimer’s Disease Research”, Channel 7 WXYZ Detroit, Jerry Hodak. UNIVERSITY COMMUNITY ACTIVITIES Leadership University of Utah: Mar 2006 – Member, Steering Committee for Research Strategic Planning, School of Medicine Dec 2005 – Member, Steering Committee, Center on Aging Sep 2005 – Member, Psychiatry Chair Search Committee, School of Medicine University of Michigan: 2003 Faculty Search Committee, Division of Neuropsychology, Department of Psychiatry 2002 Interim Chair, Appointments, Promotions, and Awards Committee, Department of Neurology 2000 – Member, Faculty Network for the Cultural Competency Curriculum 2000 – Member, Appointments, Promotions, and Awards Committee, Department of Neurology 2000 – 2001 Executive Committee, Institute of Gerontology 1998 – Mentor Panel, Research Development Core of the University of Michigan Claude Pepper Older Americans Independence Center 1996 – Multidisciplinary Advisory Group, Postdoctoral Training Program in Professional Psychology 1994 – Data and Safety Monitoring Board, General Clinical Research Center 1994 – 1999 Executive Committee, Integrated Geriatric Fellowship Program 1994 – 1995 Department Coordinator, Advances in Internal Medicine Course 1992 – Project Reviewer, General Clinical Research Center 1991 – Geriatric Center Clinical Coordinating Committee 1991 – 1997 Geriatric Center Facilities Planning Committee 1991 – 1995 Faculty Recruitment Committee, Department of Neurology 1990 – Executive Committee, Michigan Alzheimer’s Disease Research Center 1986 – 1987 Chairman, Database Management Committee, Positron Emission Tomography Center 1984 – 1990 Utilization Review, Physician Advisor Courses Taught University of Michigan: 2001 Hartford Integrative Geriatric Seminar, School of Social Work
  12. 12. 2000 Societal Analysis of Aging (HMP 673), School of Public Health 1997, 1998 Independent Study in Neurology, Neurobiology of Alzheimer's Disease and Related Dementias 1997-2002 Introduction to the Patient, Clinical Skills Laboratory, Component I 1993-2004 Neuroscience Sequence, Component II 1984-2005 Neurology 731, Junior Clerkship 1984-2005 Neurology 841, Elective Senior Clerkship 1984-2005 Presentations at Neurology Grand Rounds 1985, 89, 95, 97 Senior Clinical Pharmacology and Therapeutics (PHMRX-D.101.V) 1992-1995 Professor’s Rounds, Ann Arbor Veterans Administration Hospital 1985-1993 Neural and Behavioral Science 600 1985, 1988 Neuroscience 731 1985 Dental Neurosciences 503 1984 Medical Student Career Counselor 1984 Preceptor, Introduction to Clinical Sciences 600 1984 Senior Year Counselor University of Michigan Postgraduate Program: Nov 3, 2001 “Recognition, Initial Assessment and Diagnosis of Alzheimer’s Disease”, Pathways to More Effective Treatments of Dementia, Livonia Marriott, Livonia, MI Nov 12, 1998 “Update on Alzheimer’s Disease and Other Dementias”, Advances in Neurology and Geriatric Psychiatry Sep 4, 1997 "Disorders that Mimic Alzheimer's Disease", Neurological and Behavioral Disorders in the Elderly Mar 12, 1997 "Dementia Update", Family Practice 1997: 21st Annual Spring Review Course Sep 6, 1996 "Panel Discussion on the Care of the Cognitively Impaired Patient: Autonomy, Substituted Judgement, Research and Teaching”, Critical Clinical Issues in the Care of Older Adults: Ethics and Managed Care Apr 25, 1995 “Dementia Care in the Age of Health Reform and Malpractice”, 23rd Annual Spring Update on Advances in Internal Medicine, Mar 15, 1994 Family Practice 1994: 18th Annual Spring Review Course, “New Practical Considerations in Treating Dementia” Apr 30, 1993 “Current Approaches to the Evaluation of Dementia”, 21st Annual Spring Update on Advances in Internal Medicine, Mar 19, 1993 “Alzheimer Disease”, Family Practice 1993: 17th Annual Spring Review Course, Dec 11, 1992 General Medicine for Psychiatrists- ”Deliriium and Dementia”, “Behavioral Manifestations of Neurological Disease” Sep 10, 1992 Critical Clinical Issues in the Care of the Elderly: Drugs and Their Implications, “Alzheimer’s Disease” Series: Kellogg Interdisciplinary Team Training in Geriatrics, Ann Arbor, Michigan, “Dementia” Apr 24, 1990 “Dementia - Diagnostic Evaluation” May 22, 1990 “Dementia - Diagnostic Evaluation” Oct 2, 1990 ”Management of Dementia” Nov 6, 1990 ”Management of Dementia” Oct 19, 1987 Critical Clinical Issues in the Care of the Elderly: Illness Prevention and Early Detection, “Assessing Competence: Can the Patient Decide?” May 13, 1987 15th Annual Spring Update, Advances in Internal Medicine, “The Application of PET Scanner Techniques and Understanding Dementia” Mar 1985 Family Practice - “Evaluation of Alzheimer’s Disease” Students Supervised Graduate Students: Winter term 2004 Kelly O’Brien, MS student, Dept of Biostatistics. Supported from research incentive account for PET data analysis. Supervised by Thomas Nichol, Ph.D. Predoctoral: 1990, 91, 95 Gamil Mahmoud Tourky, MD, MSc (Dr. P.H., epidemiology) October 1990 preliminary examination, December 1991 pre-candidacy examination (proposal defense), July 1995 successful thesis defense. Thesis: “Risk factors for Alzheimer's disease: an autopsy-based case-control study” (support: Egyptian government grant). Subsequent positions: Professor, University of Tanta, Egypt
  13. 13. 1994 Sony Kilgore, University of Michigan 2nd year medical student, AFAR-John A. Hartford Foundation Medical Student Training Program in Geriatrics Fellowship Primary Research Project: An Assessment of Apolipoprotein E Frequency and Age-Related Risks of Alzheimer’s Disease (Support: AFAR-John A. Hartford Foundation Medical Student Training Program in Geriatrics Fellowship). Degree: M.D. (1996): University of Michigan. Subsequent positions: pathology resident, Cleveland Clinic Foundation 1991 Savitha Krishnan, University of Michigan 2nd year Inteflex student Primary Research Project: Predictors of Response to Treatment in Patients with Alzheimer’s Disease (support: AFAR-John A. Hartford Foundation Medical Student Training Program in Geriatrics Fellowship). Subsequent positions: obstetrics and gynecology resident, George Washington University Hospitals 1990 John W. Chen, University of Michigan 2nd-year medical student Primary Research Project: The Relationship of Mini-mental State Examination (MMSE) and Cerebral Glucose Metabolism in Alzheimer’s Disease (support: AFAR-John A. Hartford Foundation Medical Student Training Program in Geriatrics Fellowship). Subsequent positions: Neurology resident, UCLA 1989 John W. Chen, University of Michigan 1st-year medical student Primary Research Project: A Comparison of SPECT and PET Functional Brain Imaging in Dementia (support: AFAR-John A. Hartford Foundation Medical Student Training Program in Geriatrics Fellowship) 1988 Holly Brenner (Gross), University of Michigan 2nd-year medical student Primary Research Project: A Comparison of Blood Flow and Glucose Metabolic Rate in the Brains of Patients with Progressive Supranuclear Palsy Using Positron Emission Tomography (support: University of Michigan School of Medicine Biomedical Research Council). Subsequent positions: ophthalmology resident, University of Michigan Hospitals 1988 Mary S. Hansen (Grant), University of Michigan 2nd-year medical student Primary Research Project: The Effects of Pramiracetam and THA on Local Rates of Cerebral Glucose Metabolism as Measured with 18-Fluoro-deoxy-D-glucose Positron Emission Tomography in Patients with Alzheimer’s Disease (support: University of Michigan School of Medicine Biomedical Research Council). Subsequent positions: psychiatry resident, University of Michigan Hospitals 1987 Mary S. Hansen (Grant), University of Michigan 1st-year medical student Primary Research Project: Lateral and Mesial Temporal Glucose Metabolism in Alzheimer’s Disease (support: University of Michigan School of Medicine Biomedical Research Council) 1985 Jeff Wilt, University of Michigan 2nd-year medical student Primary Research Project: A Comparison of Arterial versus Arteriovenous Sampling in the Measurement of Glucose Metabolism by Positron Emission Tomography (support: University of Michigan School of Medicine Biomedical Research Council). Subsequent positions: orthopedic surgery resident Geriatric Medicine Fellow Research: Oct 99 – Oct 00 Delia Ochoa, D.O. Degree: DO (1996): Michigan State University; Fellowship: University of Michigan. Primary Research Project: Identifying Dementia in Depressed Elderly Patients (support: V.A. Geriatric Medicine Fellowship). Subsequent positions: Physician, Holy Cross Medical Group (Pompano, FL). Postdoctoral: 2005 – current David R. Shprecher, D.O. Degree: DO (2003): Lake Erie College of Osteopathic Medicine; Residency: University of Utah. Primary Research Project: Pilot PET Collaborative Imaging Trial. Subsequent Positions: Neurology resident, University of Utah (Salt Lake City, UT). 2004 - current Paul Motika, M.D. Degree: MD (2003): University of Rochester; Residency: University of Michigan. Primary Research Project: A case of Creutzfeldt-Jakob disease presenting clinically and radiographically as AD (support: unknown). Subsequent Positions: Neurology Resident, University of Rochester School of Medicine & Dentistry, NY. Apr 01 – Mar 06 Kenneth Langa, M.D. Degree: MD (1994): University of Chicago; Residency: Internal Medicine, University of Michigan. Primary Research Project: Identifying Cases and Costs of Dementia in the U.S. (support: NIA K08 award, K08-AG19180). Subsequent positions: Lecturer and Assistant
  14. 14. Professor of Internal Medicine, Faculty Associate, Institute for Social Research, University of Michigan (Ann Arbor, MI). 2002 - 2003 Pam Alvarez, M.D. Degree: MD (1998): Chicago Medical School; Residency: University of Michigan. Primary Research Project: Clinical and pathological features of early-onset familial AD caused by a novel (Leu241HIS) presenilin-1 mutation (support: unknown). Subsequent Positions: Private Practice (Tacoma, WA). 2001 - 2003 David Cohen, M.D. Degree: MD (2000): New Jersey Medical School; Internship, Residency, Fellowship: University of Michigan. Primary Research Project: Sporadic Creutzfeldt-Jokob disease presenting with nonconvulsive status epilepticus (support: unknown). Subsequent Positions: Neurologist, Robert Wood Johnson University Hospital (New Brunswick, NJ). 2001 - 2002 Amanda Peltier, M.D. Degree: MD (1998): Ohio State College of Medicine; Residency (2002): Neurology, University of Michigan. Primary Research Project: Two concurrent cases of early-onset sporadic Creutzfeldt-Jakob disease in Michigan (support: unknown). Subsequent Positions: Assistant Professor of Neurology, Vanderbilt University (Nashville, TN). 2001 - 2002 Patience Reading, M.D. Degree: MD (unknown): University of Texas Southwestern; Residency/Fellowship: Internal Medicine, University of Michigan. Primary Research Project: Two concurrent cases of early- onset sporadic Creutzfeldt-Jokob disease in Michigan (support: unknown). Subsequent Positions: Neurologist, Austin Diagnostic Clinic (Austin, TX). 2001 - 2002 Ming Hong, M.D. Degree: MD (unknown): Peking Union Medical College; Residency: University of Michigan. Primary Research Project: Spontaneous intracranial hypotension causing reversible frontotemporal dementia (support: unknown). Subsequent Positions: Private Practice (Washington, DC). Mar 00 – Mar 01 Eui-Ju Son, M.D., Assistant Professor of Neurology, University of Michigan Degree: MD (1988) and Residency: Chonnam University (South Korea). Primary Research Project: Extrapyramidal Signs in Dementia with Lewy Bodies and Alzheimer’s Disease (support: Korean Funds). Subsequent positions: Assistant Professor of Neurology, Seonam University (Kwangju, South Korea). Jul 99 – 01 Sinfree Makoni Ph.D., Associate Professor of Linguistics, University of Cape Town (South Africa), DuBois-Mandela-Rodney Postdoctoral Fellow, Center for Afro-American and African Studies Degree: PhD, Linguistics (1989): University of Edinburgh, Scotland. Primary Research Project: Language and Dementia Among African Americans (support: University of Michigan funds), Pilot Grant: Michigan Center for Urban African American Aging Research (support: NIH Grant P30-AG15281). Subsequent positions: Associate Professor Communication Sciences and Disorders, Long Island University (Brooklyn, NY); Professor, Center For Aging, University of Cape Town (South Africa). 1999 – 2001 Paolo Moretti, M.D. Degree: MD (1990): University of Padua, Italy; Residency: University of Michigan. Primary Research Project: Early-onset familial Alzheimer’s disease and spastic paraparesis associated with a novel insertional mutation of the presenilin 1 gene (support: unknown). Subsequent Positions: Assistant Professor of Neurology and Molecular and Human Genetics, Baylor College of Medicine (Houston, TX). Jul 97 – Jun 01 Andrea Bozoki, M.D. Degree: MD (1993): SUNY Downstate; Residency: Neurology, University of Michigan. Primary Research Project: Functional MRI of Memory Encoding versus Retrieval in Normal Elderly and Alzheimer Disease (support: HRSA grant D31-AH90005 (2 years); NIH Grant T32-AG00114). Subsequent positions: Assistant Professor, Michigan State University (Lansing, MI). Jul 95 – Jun 97 Judith Heidebrink, M.D. (1994): University of Texas Southwestern; Residency: Neurology, University of Michigan. Primary Research Project: Neuropharmacological Challenges in Dementia (support: HRSA grant D31-AH90005; NIH grant T32-NS07222). Subsequent/current positions: Lecturer and Assistant Professor, Department of Neurology, University of Michigan (Ann Arbor, MI). Jul 93 – Jun 95 Daniel Murman, M.D. Degree: M.D. (1989): University of Nebraska; Residency: Neurology, University of Michigan. Primary Research Project: The Effect of Apolipoprotein E on Clinical Features of Dementia
  15. 15. (support: NIH Grant T32-NS07222; HRSA grant D31-AH90005; NIH grant T32-AG00114). Subsequent positions: Lecturer of Neurology, Assistant Professor of Physical Medicine and Rehabilitation (College of Osteopathic Medicine) and Department of Medicine (College of Human Medicine, Center for Clinical Neuroscience and Ophthalmology), Michigan State University. Current positions: Director, Geriatric Neurology and Memory Disorders Clinic, Clinical Center, Michigan State University, Lansing MI; Coordinator, Michigan Dementia Postmortem Network, Michigan State University (Lansing, MI).
  16. 16. BIBLIOGRAPHY Norman L. Foster, M.D. ORIGINAL PUBLICATIONS 1. Foster NL and Campbell B. The effect of diphenylhydantoin on the microbial assay of serum folate, Clinical Biochemistry, 1976, 9, 22-23. 2. Foster NL. Progressive supranuclear palsy and hyperkalemic periodic paralysis. Archives of Neurology, 1980, 37, 461-446. 3. Foster NL, Wing SD, and Bray PF. Metrizamide ventriculography in the diagnosis of syringomyelia. Neurology, 1980, 30, 1323-1326. 4. Chase TN, Brooks RA, DeLaPaz RL, DiChiro G, Durso R, Fedio P, Foster NL, Kessler RM, Kornblith PL, Kufta CV, Manning RG, Newmark ME, Patronas NJ, Porter R, Sato S, Smith BH, and Theodore WH. Positron emission tomographic studies of epilepsy, brain tumors, and Alzheimer’s disease. Psychopharmacology Bulletin, 1982, 18(3):3-6. 5. Foster NL, Chase TN, Denaro A, Hare TA, and Tamminga CA. THIP treatment of Huntington’s disease. Neurology, 1983, 33, 637-639. 6. Foster NL, Chase TN, Fedio P, Patronas NJ, Brooks RA, and DiChiro G. Alzheimer’s disease: focal cortical changes shown by positron emission tomography. Neurology, 1983, 33, 961-965. 7. LeWitt PA, Ward CD, Larsen TA, Raphaelson MI, Newman RP, Foster NL, Dambrosia J, and Calne DB. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology, 1983, 33, 1009-1014. 8. Chase TN, Foster NL, Fedio P, Brooks R, Mansi L, and DiChiro G. Regional cortical dysfunction in Alzheimer’s disease as determined by positron emission tomography. Annals of Neurology, 1984, 15, S170-S174. 9. Chase TN, Foster NL, Fedio P, Brooks R, Mansi L, Kessler R, and DiChiro G. Gilles de la Tourette syndrome: studies with fluorine-18-labeled fluorodeoxyglucose positron emission tomographic method. Annals of Neurology, 1984, 15, S175. 10. Karson CN, Burns RS, LeWitt PA, Foster NL, and Newman RP. Blink rates and disorders of movement. Neurology, 1984, 34, 677-678. 11. Foster NL, Newman RP, LeWitt PA, Gillespie MM, Larson TA, and Chase TN. Peripheral beta-adrenergic blockade treatment of parkinsonian tremor. Annals of Neurology, 1984, 16, 505-508. 12. Foster NL, Newman RP, LeWitt PA, Gillespie MM, and Chase TN. Treatment of resting tremor by beta-adrenergic blockade. American Heart Journal, 1984, 108, 1173-1177. 13. Chase TN, Fedio P, Foster NL, Brooks R, DiChiro G, and Mansi L. Cortical localization of WAIS subtest performance by fluorodeoxyglucose positron emission tomography. Archives of Neurology, 1984, 41, 1244-1247. 14. Foster NL, Chase TN, Mansi L, Brook R, Fedio P, Patronas NJ, and DiChiro G. Cortical abnormalities in Alzheimer’s disease. Annals of Neurology, 1984, 16, 649-654. 15. Grimes AM, Grady CL, Foster NL, Sunderland T, and Patronas NJ. Central auditory function in Alzheimer’s disease. Neurology, 1985, 35, 352-358. 16. Hurst JH, LeWitt PA, Burns RS, Foster NL, and Lovenberg W. CSF dopamine-B-hydroxylase activity in parkinsonian patients. Neurology, 1985, 35, 565-568. 17. Newman RP, LeWitt PA, Shults C, Bruno G, Foster NL, Chase TN, and Calne, DB. Dystonia: treatment with bromocriptine. Clinical Neuropharmacology, 1985, 8, 328-333. 18. Foster NL, Tamminga CA, O’Donohue TL, Taninioto K, Bird ED, and Chase TN. Brain choline acetyltransferase activity and neuropeptide Y concentrations in Alzheimer’s disease. Neuroscience Letters, 1986, 63, 71-75. 19. Irving CS, Marks L, Klein PD, Foster NL, Gadde PL, Chase TN, and Samuel D. New evidence for taurine biosynthesis in man obtained from 1802 inhalation studies. Life Sciences, 1986, 38, 491-495. 20. Foster NL, Chase TN, Patronas NJ, Gillespie MM, and Fedio P. Cerebral mapping of apraxia in Alzheimer’s disease by positron emission tomography. Annals of Neurology, 1986, 19, 139-143. 21. Tamminga CA, Gotts MD, Thaker GK, Alphs LD, and Foster NL. Dopamine agonist treatment of schizophrenia using N-propylnorapomorphine. Archives of General Psychiatry, 1986, 43, 398-402. 22. Mohr E, Burns G, Foster NL, Gillespie M, Cox C, Hare TA, Tamminga C, Fedio P, and Chase TN. GABA-agonist therapy of Alzheimer’s disease. Clinical Neuropharmacology, 1986, 9, 257-263. 23. Martin A, Brouwers P, Lalonde F, Cox C, Teleska P, Fedio P, Foster NL, and Chase TN. Towards a behavioral typology of Alzheimer’s patients. Journal of Clinical and Experimental Neuropsychology, 1986, 8, 594-610. 24. Tamminga CA, Foster NL, Fedio P, Bird ED, and Chase TN. Alzheimer’s disease: low cerebral somatostatin levels correlate with impaired cognitive function and cortical metabolism. Neurology, 1987, 37, 161-165. 25. Foster NL, VanDerSpek AFL, Aldrich MS, Berent S, Hichwa RH, Sackellares JC, Gilman S, and Agranoff, BW. The effect of diazepam sedation on cerebral glucose metabolism in Alzheimer’s disease as measured using positron emission tomography. Journal of Cerebal Blood Flow and Metabolism, 1987, 7, 415-420. 26. Berginer VM, Foster NL, Sadowsky M, Townsend JA, and Siegel, GJ. Psychiatric disorders in cerebrotendinous xanthomatosis. American Journal of Psychology, 1988, 145, 354-357.
  17. 17. 27. Sheridan PH, Sato S, Foster NL, Bruno G, Cox C, Fedio P, and Chase TN. Relation of EEG alpha background to parietal lobe function in Alzheimer’s disease as measured by positron emission tomography and psychometry. Neurology, 1988, 38, 747-750. 28. Foster NL, Mountz JM, Bluemlein LA, Ackermann RJ, Petry NA, and Kuhl, DE. Blood flow imaging of posterior circulation stroke. Use of technetium Tc 99m hexamethylpropleneamine oxime and single photon emission computed tomography. Archives of Neurology, 1988, 45, 687-690. 29. Foster NL, Gilman S, Berent S, Morin EM, Brown MB, and Koeppe, RA. Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. Annals of Neurology, 1988, 24, 399-406. 30. Mountz JM, Foster NL, Ackermann RJ, Bluemlein LA, Petry NA, and Kuhl, DE. SPECT imaging of Moyamoya disease using 99m-Tc-HM-PAO: comparison with computed tomography findings. Journal of Computed Tomography, 1988, 12, 247-250. 31. Foster NL, Aldrich MS, Bluemlein LA, White RF, and Berent, S. Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep. Neurology, 1989, 39, 257-261. 32. Grady CL, Grimes AM, Patronas N, Sunderland T, Foster NL, and Rapoport SI. Divided attention, as measured by dichotic speech performance, in dementia of the Alzheimer type. Archives of Neurology, 1989, 46, 317-320. 33. Aldrich MS, Foster NL, White RF, Bluemlein LA, and Prokopowicz G. Sleep abnormalities in progressive supranuclear palsy. Annals of Neurology, 1989, 25, 577-581. 34. Mountz JM, Modell JG, Foster NL, DuPree ES, Ackermann RJ, Petry NA, Bluemlein LE, and Kuhl, DE. Prognostication of recovery following stroke using the comparison of CT and technetium-99m HM-PAO SPECT. Journal of Nuclear Medicine, 1990, 31, 61-66. 35. Giordani B, Boivin MJ, Hall AL, Foster NL, Lehtinen SJ, Bluemlein LA, and Berent, S. The utility and generality of Mini-Mental State Examination scores in Alzheimer’s disease. Neurology, 1990, 40, 1894-1896. 36. Bromberg MB, Aldrich MS, Foster NL, and Berent, S. The Kluver-Bucy syndrome preceding ventricular enlargement in normal pressure hydrocephalus. Dementia, 1990, 1, 169-174. 37. Goldman R, Axelrod BN, Giordani B, Foster NL, and Berent, S. Longitudinal sensitivity of the Fuld cholinergic profile to Alzheimer’s disease. Journal of Clinical and Experimental Neuropsychology, 1992, 14, 566-574. 38. Boivin MJ, Giordani B, Berent S, Amato DA, Lehtinen S, Koeppe RA, Buchtel HA, Foster NL, and Kuhl, DE. Verbal fluency and positron emission tomographic mapping of regional cerebral glucose metabolism. Cortex, 1992, 28, 231-239. 39. Foster NL, Gilman S, Berent S, Sima AAF, D’Amato C, Koeppe RA, and Hicks, SP. Progressive subcortical gliosis and progressive supranuclear palsy can have similar clinical and PET abnormalities. Journal of Neurology, Neurosurgery, and Psychiatry, 1992, 55, 707-713. 40. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J, and the Tacrine Study Group. A controlled trial of tacrine in Alzheimer’s disease. Journal of the American Medical Association, 1992, 268, 2523-2529. 41. Kluin KJ, Foster NL, Berent S, and Gilman S. Perceptual analysis of speech disorders in progressive supranuclear palsy. Neurology, 1993, 43, 563-566. 42. Shope JT, Holmes SB, Sharpe PA, Goodman C, Izenson S, Gilman S, and Foster NL. Services for persons with dementia and their families: a survey of information and referral agencies in Michigan. Gerontologist, 1993, 33, 529-533. 43. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI, and Tacrine Study Group. A 30- week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. Journal of the American Medical Association, 1994, 271, 985-991. 44. Lynch T, Sano M, Marder KS, Bell KL, Foster NL, Defendini RF, Sima, AAF, Keohane C, Nygaard TG, Fahn S, Mayeaux R, Rowland LP, and Wilhelmsen KC. Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology, 1994, 44, 1878-1884. 45. Meyer M, Koeppe RA, Frey KA, Foster NL, and Kuhl DE. PET measure of benzodiazepine receptors in Alzheimer’s disease. Archives of Neurology, 1995, 52, 314-317. 46. Alexander NB, Mollo JM, Giordani B, Ashton-Miller JA, Schultz AB, Grunawalt JA, Foster NL. Maintenance of balance, gait patterns and obstacle clearance in Alzheimer’s disease. Neurology, 1995, 45, 908-914. 47. Minoshima A, Frey KA, Koeppe RA, Foster NL, and Kuhl DE. A diagnostic approach in Alzheimer’s disease using 3-dimensional stereotactic surface projections of fluorine-18-FDG PET. Journal of Nuclear Medicine, 1995, 36, 1238-1248. 48. Minoshima A, Frey KA, Foster NL, and Kuhl DE. Preserved pontine glucose metabolism in Alzheimer’s disease: a reference region for functional brain analysis. Journal of Computer Assisted Tomography, 1995, 19, 541-547. 49. McDaniel KD, Edland SD, Heyman A, and the CERAD Clinical Investigators. Relationship between level of insight and severity of dementia in Alzheimer disease. Alzheimer Disease and Associated Disorders, 1995, 9, 101-104. 50. Groom GN, Junck L, Foster NL, Frey KA, and Kuhl DE. Positron emission tomography of peripheral benzodiazepine binding sites in the microgliosis of Alzheimer's disease. Journal of Nuclear Medicine, 1995, 36, 2207-2210.
  18. 18. 51. Fontana RJ, Turgeon DK, Woolf TF, Knapp MJ, Foster NL, and Watkins PB. The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity. Hepatology, 1996, 23, 1429-1435. 52. Sima AAF, Defendini RF, Keohane C, D'Amato C, Foster NL, Parchi P, Gambetti P, Lynch T, and Wilhelmsen KC. The neuropathology of chromosome 17-linked dementia. Annals of Neurology, 1996, 39, 734-743. 53. Fisher NJ, Rourke BP, Bieliauskas L, Giordani B, Berent S, and Foster NL. Neuropsychological subgroups of patients with Alzheimer's disease. Journal of Clinical and Experimental Neuropsychology, 1996, 18, 349-370. 54. Knopman D, Schneider L, Davis K, Talwalker S, Smith F, Hoover T Gracon, S, and Tacrine Study Group. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology, 1996, 47, 166-177. 55. Butter CM, Trobe JD, Foster NL, and Berent S. Visual-spatial deficits explain visual symptoms in Alzheimer's disease. American Journal of Ophthalmology, 1996, 122, 97-105. 56. Murman DL, Foster NL, Kilgore SP, McDonagh CA, and Fink JK. Apolipoprotein E and Alzheimer's disease: strength of association is related to age of onset. Dementia, 1996, 7, 251-255. 57. Foster NL, Petersen RC, Gracon SI, Lewis K, and the Tacrine 970-6 Study Group. An enriched-population, double- blind, placebo-controlled, crossover study of tacrine and lecithin in Alzheimer's disease. Dementia, 1996, 7, 260-266. 58. Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficaro EP, Wieland DM, and Koeppe RA. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease and Parkinson's disease. Annals of Neurology, 1996, 40, 399-410. 59. Cochran EJ, Bennett DA, Cervenáková L, Kenney K, Bernard B, Foster NL, Benson DF, Goldfarb LG, and Brown P. Familial Creutzfeldt-Jakob disease with a five-repeat octapeptide insert mutation. Neurology, 1996, 47, 727-733. 60. Sano M, Ernesto C, Klauber MR, Schafer K, Woodbury P, Thomas R, Grundman M, Growdon J, Thal LJ, and Members of the Alzheimer's Disease Cooperative Study. Rationale and design of a multicenter study of selegiline and a-tocopherol in the treatment of Alzheimer disease using novel clinical outcomes. Alzheimer Disease and Associated Disorders, 1996, 10, 132-140. 61. Sano M, Ernesto C, Thomas R, Klauber Mr, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ, for the Members of the Alzheimer’s Disease Cooperative Study. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. New England Journal of Medicine, 1997, 338, 1216-1222. 62. Vander Borght T, Minoshima S, Giordani B, Foster NL, Frey KA, Berent S, and Kuhl DE. Cerebral metabolic differences in Alzheimer's and Parkinson's diseases matched for dementia severity. Journal of Nuclear Medicine, 1997, 38, 797-802. 63. Foster NL, Wilhelmsen K, Sima AAF, Jones MZ, D'Amato C, and Gilman S. Participants in the Conference. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Annals of Neurology, 1997, 41, 706-715. 64. Morris JC, Ernesto C, Schafer K, Coats M, Leon S, Sano M, Thal LJ, Woodbury P, and the Alzheimer's Disease Cooperative Study. Clinical Dementia Rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience. Neurology, 1997, 48, 1508-1510. 65. Murman DL, Giordani B, Mellow AM, Johanns JR, Little RJA, Hariharan M, and Foster NL. Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease. Neurology, 1997, 49, 153-161. 66. Minoshima S, Giordani BJ, Berent S, Frey KA, Foster NL, and Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Annals of Neurology, 1997, 42, 85-94. 67. Fisher NJ, Rourke BP, Bieliauskas LA, Giordani B, Berent S, and Foster NL. Unmasking the heterogeneity of Alzheimer's disease: case studies of individuals from distinct neuropsychological subgroups. Journal of Clinical and Experimental Neuropsychology, 1997, 19, 713-754. 68. Whall AL, Black ME, Groh CJ, Yankou DJ, Kupferschmid BJ, and Foster NL. The effects of natural environments on agitation and aggression in late stage dementia patients. American Journal Alzheimer’s Disease and Other Dementias, 1997, 12, 216-220. 69. Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, Hyman BT, Crain B, Tang M, Phelps CH, and the Alzheimer's Disease Centers Consortium on APOE and Alzheimer's Disease. Utility of the APOE genotype in the diagnosis of Alzheimer's disease. New England Journal of Medicine, 1998, 338, 506-511. 70. Foster NL. The development of biological markers for the diagnosis of Alzheimer's disease. Neurobiology of Aging, 1998, 19, 127-129. 71. Whall AL, Black ME, Groh CJ, Yankou DJ, Kupferschmid BJ, and Foster NL. Efecto del entorno natural sobre la agitación y la agresión en pacientes con estado avanzado de demencia. Metas De Enfermeria, 1998, 12-18. [Reprint, In Spanish] 72. Minoshima S, Foster NL, Nishimura S, and Kuhl DE. Glucose metabolic imaging for functional diagnosis of brain disorders: current status and prospects. Japanese Journal of Radiology, 1998, 43, 1113-1121. [In Japanese]. 73. Qizilbash N, Whitehead A, Higgins J, Wilcock G, Schneider L, Farlow M, for the Dementia Trialists' Collaboration. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Journal of the American Medical Association, 1998, 280, 1777-1782.
  19. 19. 74. Fontana RJ, deVries TM, Woolf TF, Knapp MJ, Brown AS, Kaminsky LS, Tang B-K, Foster NL, and Watkins PB. Caffeine based measures of CYP1A2 activity predict the oral clearance of tacrine. British Journal of Clinical Pharmacology, 1998, 46, 221-228. 75. Bartok JA, Wilson CS, Giordani B, Keys BA, Persad CC, Foster NL, and Berent S. Varying patterns of verbal recall, recognition, and response bias with progression of Alzheimer's disease. Aging Neuropsychology and Cognition, 1998, 4, 266-71. 76. Whall AL, Black ME, Groh CJ, Yankou DJ, Kupferschmid BJ, and Foster NL. The effects of natural environments on agitation and aggression in late stage dementia patients. Journal of Healthcare Safety, Compliance and Infection Control, 1999, 3, 31-35. [Reprint] 77. Berent S, Giordani B, Foster NL, Minoshima S, Lajiness-O'Neal R, Koeppe R, and Kuhl DE. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. Journal of Psychiatric Research, 1999, 33, 7-16. 78. Kuhl DE, Koeppe RA, Minoshima S, Snyder SE, Ficaro EP, Foster NL, Frey KA, and Kilbourn MR. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology, 1999, 52, 691-699. 79. Knopman DS, Berg JD, Thomas R, Grundman M, Thal LJ, Sano M, for Members of the Alzheimer's Disease Cooperative Study. Nursing home placement is related to dementia progression: experience from a clinical trial. Neurology, 1999, 52, 714-718. 80. Foster NL. Frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17): a clinician's guide. Neurologist, 1999, 5, 213-221. 81. Sima AAF, D'Amato C, and Foster NL. Neuropathology of chromosome-17-linked dementia. Dementia and Geriatric Cognitive Disorders, 1999, 10 (suppl 1), 61-63. 82. Whall AL, Black MEA, Yankou DJ, Groh CJ, Kupferschmid BJ, Foster NL, and Little R. Nurse aides' identification of onset and level of agitation in late stage dementia patients. American Journal of Alzheimer’s Disease and Other Dementias, 1999, 14, 202-206. 83. Foster NL, Minoshima S, Johanns J, Little R, Heumann ML, Kuhl DE, and Gilman S. PET measures of benzodiazepine receptors in progressive supranuclear palsy. Neurology, 2000, 54, 1768-1773. 84. Foster NL, Gombosi E, Teboe C, and Little RJA. Balanced centralized and distributed database design in a clinical research environment. Statistics in Medicine, 2000, 19, 1531-1544. 85. Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, and Koeppe RA. Limited donepezil inhibition of acetylcholinesterase measured with PET in living Alzheimer cerebral cortex. Annals of Neurology, 2000, 48, 391-395. 86. Teri L, Logsdon RG, Peskind E, Raskind M, Weiner M, Tractenberg RE, Foster NL, Schneider LS, Sano M, Whitehouse P, Tariot P, Mellow AM, Auchus AP, Grundman M, Thomas RG, Schafer K, Thal LJ, and Members of the Alzheimer's Disease Cooperative Study. Treatment of agitation in Alzheimer’s disease patients: a randomized placebo controlled clinical trial. Neurology, 2000, 55, 1271-1278. 87. Kluin KJ, Gilman S, Foster NL, Sima AAF, D'Amato C, Bruch LA, Bluemlein L, Little RJ, and Johanns J. Neuropathologic correlates of dysarthria in progressive supranuclear palsy. Archives of Neurology, 2001, 58, 265-269. 88. Zubieta JK, Koeppe RA, Frey KA, Kilbourn MR, Mangner TJ, Foster NL, and Kuhl DE. Assessment of muscarinic receptor concentrations in aging and Alzheimer's disease with [11C]NMPB and PET. Synapse, 2001, 39, 275-287. 89. Bozoki A, Giordani B, Heidebrink JL, Berent S, and Foster NL. Mild cognitive impairments predict dementia in non- demented elderly with memory loss. Archives of Neurology, 2001, 58, 411-416. 90. Connell CM, Shaw BA, Holmes SB, and Foster NL. Caregiver's attitudes toward participation in Alzheimer's disease research: implications for recruitment and retention. Alzheimer Disease and Associated Disorders, 2001, 15, 137-145. 91. Doody RS, Dunn JK, Clark CM, Farlow M, Foster NL, Liao T, Gonzales N, Lai E, and Massman P. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer’s disease. Dementia and Geriatric Cognitive Disorders, 2001, 12, 295-300. 92. Minoshima S, Foster NL, Sima AAF, Frey KA, Albin RL, and Kuhl DE. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Annals of Neurology, 2001, 50, 358-365. 93. Foster NL. Barriers to treatment: the unique challenges for physicians providing dementia care. Journal of Geriatric Psychiatry and Neurology, 2001, 14, 188-198. 94. Lynch T, Sano M, Marder KS, Bell KL, Foster NL, Defendini RF, Sima AA, Keohane C, Nygaard TG, Fahn S, Mayeux R, Rowland LP, and Wilhelmsen KC. Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology, 2001, 57 Suppl 3, S39-S45. 95. Hong M, Shah GV, Adams KM, Turner RS, and Foster NL. Spontaneous intracranial hypotension causing reversible frontotemporal dementia. Neurology, 2002, 58, 1285-1287. 96. Minoshima S, Foster NL, Petrie EC, Albin RL, Frey KA, and Kuhl DE. Neuroimaging in dementia with Lewy bodies: metabolism, neurochemistry, and morphology. Journal of Geriatric Psychiatry and Neurology, 2002, 15, 200-209.
  20. 20. 97. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas R, Thal L, for the Alzheimer's Disease Cooperative Study. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. Journal of the American Medical Association, 2003, 289, 2819-2826. 98. Foster NL. Validating FDG-PET as a biomarker for frontotemporal dementia. Experimental Neurology, 2003, 184 (Supplement 1), S2-S8. 99. Singer C, Tractenberg RE, Kaye J, Schafer K, Gamst A, Grundman M, Thomas R, Thal LJ, for the Alzheimer’s Disease Cooperative Study. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer’s disease. Sleep, 2003, 26, 893-901. 100. Higdon R, Foster NL, Koeppe RA, DeCarli CS, Jagust WJ, Clark CM, Barbas NR, Arnold SE, Turner RS, Heidebrink JL, and Minoshima S. A comparison of classification methods for differentiating fronto-temporal dementia from Alzheimer’s disease using FDG-PET imaging. Statistics in Medicine, 2004, 23, 315-326. 101. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen P, Bennett DA, Foster NL, Jack C, Galasko D, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyck C, Mintzer J, Zamrini EY, Cahn-Weiner D, Thal LJ, and the Alzheimer’s Disease Cooperative Study. Mild cognitive impairment can be distinguished from Alzheimer's disease and normal aging for clinical trials. Archives of Neurology, 2004, 61, 59-66. 102. Banaszak-Holl J, Fendrick AM, Foster NL, Herzog AR, Kabeto MU, Kent DM, Straus WL, and Langa KM. Predicting nursing home admission: estimates from a seven year follow-up of a nationally representative sample of older Americans. Alzheimer Disease and Associated Disorders, 2004, 18, 83-89. 103. Langa KM, Larson EB, Wallace RB, Fendrick AM, Foster NL, Kabeto MU, Weir DR, Willis RJ, and Herzog AR. Out- of-pocket health care expenditures among older Americans with dementia. Alzheimer Disease and Associated Disorders, 2004, 18, 90-98. 104. Moretti PM, Lieberman AP, Wilde E, Giordani B, Kluin KJ, Koeppe RS, Minoshima S, Kuhl DE, Seltzer WK, and Foster NL. Novel insertional presenilin 1 mutation causing AD with spastic paraparesis. Neurology, 2004, 62, 1865-1868. 105. Langa KM, Foster NL, Larson EB. Mixed Dementia: Emerging Concepts and Therapeutic Implications. JAMA 2004;292:2901-8. 106. Tasdizen T, Awate S, Whitaker R, Foster NL. MRI Tissue Classification with Neighborhood Statistics: A Nonparametric, Entropy-Minimizing Approach. Proceedings of the 8th International Conference on Medical Image Computing and Computer Assisted Intervention (MICCAI). 2005. 107. Morris JC, Weintraub S, Chui HC, Cummings J, Decarli C, Ferris S, Foster NL, Galasko D, Graff-Radford N, Peskind ER, Beekly D, Ramos EM, Kukull WA. The Uniform Data Set (UDS): Clinical and Cognitive Variables and Descriptive Data From Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006 Oct/Dec;20(4):210-216. REVIEW ARTICLES 1. Foster NL. The clinical diagnosis of Alzheimer’s disease. Michigan Postgraduate Review,1991,8,107-113. 2. Hong M, Shah GV, Adams KM, Turner RS, Foster NL. Spontaneous intracranial hypotension causing reversible frontotemporal dementia. Dementia Review Series (Sweden), 2003, 5, 9-11 3. Langa KM, Foster NL, Larson EB. Mixed Dementia: emerging concepts and therapeutic implications. Journal of the American Medical Association, 2004, 292, 2901-2908. BOOKS & BOOK CHAPTERS 1. Chase TN, Foster NL, Fedio P, DiChiro G, Patronas NJ. Alzheimer’s disease: local cerebral metabolism studies using the fluoro-deoxyglucose-positron emission tomographic techniques. In: D Samuel, S Ageri, S Gershon, VE Grimm, and G Toffano, (Eds.), Aging of the Brain. New York: Raven Press, 1983, 43-154. 2. Chase TN, Foster NL, Fedio P, Mansi L, Brooks R, Kessler R, DiChiro G. Cognitive and cerebral metabolic function in early and advanced Alzheimer’s disease. In: C Fieschi, GL Lenzi, and CW Loeb, (Eds.), Effects of Aging on Regulation of Cerebral Blood Flow and Metabolism. Basel: Karger, 1984, 176-179. 3. Chase TN, Foster NL. Alterations in local cortical glucose metabolism in Alzheimer’s disease. In: NA Lassen, KA Hossmarin, M Reivich, A Agnoli, and J Cahn, (Eds.), Drugs and Diseases, 1984, Vol 1, Number 3. London: John Libbey Eurotex Ltd., 1984, 175-180. 4. Chase TN, Brooks RA, DiChiro G, Fedio P, Foster NL, Kessler RA, Mansi L, Manning RG, Patronas NJ. Focal cortical abnormalities in Alzheimer’s disease. In: T Greitz, DH Ingvar, and L Widen, (Eds.), The Metabolism of the Human Brain Studied with Positron Emission Tomography. New York: Raven Press, 1985, 433-440. 5. Foster NL, Chase TN. Huntington’s disease. In: RT Johnson, (Ed.), Current Therapy in Neurology Disease. Philadelphia: B. C. Decker, Inc., 1985, 244-247. 6. Foster NL. Age-related changes in the human nervous system. In: HG Mueller, VC Geoffrey, (Eds.), Communication Disorders in Aging: Assessment and Management. Washington D. C.: Gallaudet University Press, 1987, 3-35.
  21. 21. 7. Foster NL. Brain imaging as a useful tool in the diagnosis of dementia. In: HJ Altman, BN Altman, (Eds.), Alzheimer’s and Parkinson’s Diseases. Recent Advances in Research and Clinical Management. New York: Plenum Press, 1989, 19-38. 8. Foster NL. Dementia in movement disorders. In: WRW Martin, (Ed.), Functional Imaging in Movement Disorders. Cleveland: CRC Press, 1990, 215-232. 9. Mayeux RP, Foster NL, Rossor M, Whitehouse PJ. Clinical evaluation of dementia. In: PJ Whitehouse, (Ed.), Dementia. Philadelphia: F. A. Davis Co., 1993, 92-129. 10. Foster NL. PET imaging. In: RD Terry, R Katzman, KL Bick, (Eds.), Alzheimer Disease. New York: Raven Press, 1994, 87-103. 11. Farlow MR, Brashear A, Hui S, Schneider L, Unverzagt F, Tacrine Study Group. The effects of tacrine in patients with mild versus moderate stage Alzheimer's disease. In: K Iqbal, JA Mortimer, B Winblad, HM Wisniewski, (Eds.), Research Advances in Alzheimer's Disease and Related Disorders. New York: John Wiley & Sons, Ltd., 1995, 283-292. 12. Minoshima S, Frey KA, Foster NL, Kuhl DE. Diagnostic application of PET in dementia. In: Y Ishii, Y Yonekura, Y Fujibayashi, N Sadato, (Eds.), Recent Advances in Biomedical Imaging. New York: Elsevier, 1997, 103-107. 13. Foster NL, Minoshima S, Kuhl DE. Brain imaging. In: RD Terry, R Katzman, KL Bick, SS Sisodia, (Eds.), Alzheimer Disease. 2nd ed. New York: Raven Press, 1999, 67-93. 14. Heidebrink JL, Foster NL. Dementia. In: SM Shah, KM Kelly, (Eds.), Emergency Neurology: Principles and Practice. New York: Cambridge University Press, 1999, 312-325. 15. Minoshima S, Foster NL, Cross DJ, Kuhl DE. PET investigations of dementia. In: N Tamaki, E Tsukamoto, Y Kuge, C Katoh, K Morita, (Eds.), Positron Emission Tomography in the Millennium: Proceedings of the International PET Symposium held in Hokkaido, Japan 24-26th September 1999. Amsterdam: Elsevier Science B. V., 2000, 17-22. 16. Bozoki A, Giordani B, Heidebrink JL, Berent S, Foster NL. Synopsis of: mild cognitive impairments predict dementia in non-demented elderly with memory loss. In: B Vellas, J Fitten, B Winblad, H Feldman, M Grundman, E Giacobini, A Kurz, (Eds.), Research and Practice in Alzheimer's Disease, Volume 6. Paris: Serdi, 2002, 43-47. 17. Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, Foster NL, Schneider LS, Sano M, Whitehouse P, Tariot P, Mellow AM, Auchus AP, Grundman M, Thomas RG, Schafer K, Thal L. J., and Members of the Alzheimer's Disease Cooperative Study. Treatment of agitation in Alzheimer's disease: an investigation of haloperidol, trazodone and behavior management techniques. In: B Vellas, J Fitten, B Winblad, H Feldman, M Grundman, E Giacobini, A Kurz, (Eds.), Research and Practice in Alzheimer's Disease, Volume 6. Paris: Serdi, 2002, 232-236. 18. Foster NL, Bozoki A, Minoshima S, Kuhl DE, Giordani B, Berent S. Isolated memory impairment: clues from imaging and follow-up studies. In: G Binetti, A Alberici, R Ghidoni, O Zanetti, (Eds.), The Shadow Line from Normal Aging to Dementia. Brecia: IRCCS Centro San Giovanni di Dio FBF, 2002, 27-35. 19. Foster NL. Neuropsychiatry of dementing disorders. In: BS Fogel, RB Schiffer, SM Rao. Neuropsychiatry, 2nd ed. New York: Lippincott, Williams and Wilkins, 2003, 1034-1070. 20. Foster NL. Neuroimaging techniques: CT, MRI, SPECT, PET. In: RW Richter, BZ Richter, (Eds.), Alzheimer's Disease: A Physician's Guide to Practical Management. Totowa, NJ: Humana Press Inc., 2004, 89-102. 21. Foster NL, Koeppe RE, Giordani BJ, Nichols TE, Lieberman AP. Variations of the phenotype in frontotemporal dementias. In: Cummings J, Hardy J, Poncet M, Christen Y, eds. Genotype - Proteotype - Phenotype Relationships in Neurodegenerative Diseases. Series: Research and Perspectives in Alzheimer's Disease. Berlin: Spinger-Verlag, 2005:139-52 22. Foster NL. The Clinical Issues. In: Herholz K, Perani D, Morris C (Eds.), The Dementias: Early Diagnosis and Evaluation. New York: Taylor & Francis, 2006, 1-31. ABSTRACTS 1. Foster NL, Patronas NJ, DeLaPaz R, DiChiro G, Brooks R, Chase TN, Fedio P, DeNaro A, Durso R. PET studies of Alzheimer’s disease. Neurology, 1982, 32, A167. 2. LeWitt PA, Ward CD, Larsen TA, Raphaelson MI, Newman RP, Foster NL, Dambrosia J, Calne DB. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology, 1982, 32, A181. 3. Foster NL, Chase TN, Hare TA. THIP treatment of Huntington’s disease. Neurology, 1982, 32, A206. 4. Newman RP, LeWitt PA, Raphaelson MI, Foster NL, Calne DB, Chase TN. Dystonia: therapy with dopaminergic ergot derivatives. Annals of Neurology, 1982, 12, 82. 5. Foster NL, Chase TN, Patronas NJ, Brooks RL, DiChiro G, Fedio P. Cerebral mapping of apraxia by positron emission tomography in Alzheimer’s disease. Annals of Neurology, 1982, 12, 89. 6. Foster NL, Chase TN. Diffuse involvement in progressive aphasia. Annals of Neurology, 1983, 13, 224. 7. Foster NL, Hare TA, Chase TN. Spinal fluid GABA in Alzheimer’s disease. Neurology, 1983, 33 (Suppl 2), 68. 8. Karson CN, Foster NL, LeWitt PA, Jeste DV, Newman RP, Bruno FS. Blink rates and disorders of movement. Neurology, 1983, 33(Suppl 2), 129.
  22. 22. 9. Foster NL, Newman RP, LeWitt PA, Gillespie MM, Chase TN, Larsen TA. Beta-blockade of parkinsonian tremor. Annals of Neurology, 1983, 14, 134. 10. Chase TN, Foster NL, Mansi L. Alzheimer’s disease and the parietal lobe. Lancet, 1983, ii, 225. 11. Foster NL, Chase TN. Relative preservation of frontal glucose metabolism in early Alzheimer’s disease. Abstracts – Society for Neuroscience, 1983, 9, 270. 12. Grimes AM, Grady CL, Foster NL, Sunderland T. Performance of the SSW in Alzheimer’s disease. ASHA, 1983, 25, 134. 13. Pikus AT, Vernon EK, Grady CL, Foster NL, Sunderland T. Audiologic profile in Alzheimer’s disease. ASHA, 1983, 25, 134. 14. Foster NL, Cox C, Harland AL, Fedio P, Chase TN. Vasopressin in Alzheimer’s disease (Reply). Neurology, 1983, 33, 1635. 15. Bruno G, Foster NL, Fedio P, Mohr E, Cox C, Gillespie MM, Chase TN. THIP therapy of Alzheimer’s disease. Neurology, 1984, 34(Suppl 1), 225. 16. Foster NL, Tamminga CA, O’Donohue TL, Chase TN. PET-directed study of neuropeptide Y in Alzheimer’s disease. Abstracts – Society for Neuroscience, 1984, 10, 173. 17. Martin A, Bouwers P, Lalonde F, Cox C, Foster NL, Chase TN, Fedio F. Subgroups of Alzheimer’s patients: neuropsychological and cerebral metabolic profiles. Abstracts – Society for Neuroscience, 1984, 10, 310. 18. Tamminga CA, Tanimoto K, Foster NL, Chase TN. Alzheimer’s disease: somatostatin loss in area of maximal fluorodeoxyglucose reduction. Neurology, 1985, 35(Suppl 1), 183. 19. Sheridan PH, Sato S, Foster NL, Bruno G, Fedio P, Chase TN. Alpha background and parietal lobe function (positron emission tomography, psychometry) in Alzheimer’s disease. Electroencephalography and Clinical Neurophysiology, 1985, 61, 33P. 20. Foster NL, VanDerSpek A, Sackellares JC, Aldrich MS, Hichwa RH, Gilman S, Agranoff BW. The effect of diazepam sedation on cerebral glucose metabolism in Alzheimer’s disease. Abstracts – Society for Neuroscience, 1985, 11, 1126. 21. Foster NL, Gilman S, Hichwa RD. Comparison of brain metabolism in Alzheimer’s disease and progressive supranuclear palsy using 18-F-fluoro-2-deoxyglucose positron emission tomography. Presented at the Michigan Neurological Association 18th Annual Meeting, Detroit, November 16, 1985. 22. Tamminga CA, Foster NL, Chase TN. Reduced brain somatostatin levels in Alzheimer’s disease. New England Journal of Medicine, 1985, 313, 1294-1295. 23. Foster NL, Chase TN. Cerebral metabolic rate of glucose and Alzheimer’s disease. Journal of Cerebal Blood Flow and Metabolism, 1986, 6, 125. 24. Foster NL, Gilman S, Berent S, Hichwa RD. Distinctive patterns of cerebral cortical glucose metabolism in progressive supranuclear palsy studied with positron emission tomography. Neurology, 1986, 36(Suppl 1), 338. 25. Wilt JL, Foster NL, Hutchins GD, Rothman ED, Rothley JM, Hichwa RD. A comparison of arterial versus arteriovenous sampling in the measurement of glucose metabolism by positron emission tomography. Clinical Research, 1986, 34, 1011A. 26. Townsend J, Foster NL, Siegel GJ. Cerebrotendinous xanthomatosis: diagnostic strategies in the patient with normal plasma cholestanol levels. Presented at the Michigan Neurological Association 19th Annual Meeting, Detroit, November 25, 1986. 27. Foster NL, Berent S, Brown MB, Gilman S, Hichwa RD. Cerebral cortical metabolism reflects performance on the Wechsler adult intelligence scale. Neurology, 1987, 37(Suppl 1), 169. 28. Berent S, Foster NL, Gilman S, Hichwa R, Lehtinen S. Patterns of cortical 18-F-FDG metabolism in Alzheimer’s and progressive supranuclear palsy patients are related to the types of cognitive impairments. Neurology, 1987, 37(Suppl 1), 172. 29. Foster NL, Gilman S, Berent S, Brown MB, Hichwa RD. Glucose hypometabolism in progressive supranuclear palsy not limited to frontal cortex. Annals of Neurology, 1987, 22, 123. 30. Townsend J, Foster NL, Siegel GJ, Salen G, Sadowsky M, Berginer VM. Psychiatric manifestations of cerebrotendinous xanthomatosis. Annals of Neurology, 1987, 22, 134. 31. Mountz JM, Foster NL, Ackermann RJ, Petry NA, Kuhl DE. Utility of Tc-99m HM PAO in evaluation of stroke. Radiology, 1987, 165(Suppl), 244. 32. Foster NL, Hansen MS, Siegel GJ, Kuhl DE. Mesial and lateral temporal glucose metabolism in aging and Alzheimer’s disease studied by PET. Neurology, 1988, 3(Suppl 1), 133. 33. Foster NL, Morin EM, Kuhl DE, Gilman S. Glucose metabolic activity in the basal ganglion and thalamus differs in progressive supranuclear palsy and Alzheimer’s disease. Neurology, 1988, 38(Suppl 1), 369. 34. Mountz JM, Foster NL, Stafford-Schuck KA, Ackermann RJ, Petry NA, Kuhl DE. Stroke prognosis using 99mTc HM PAO SPECT. Journal of Nuclear Medicine, 1988, 29(Suppl 1), 743. 35. Koeppe RA, Foster NL, Rothley JM, Kuhl DE. Determination of rate constants from dynamic FDG PET studies in degenerative brain disorders. Journal of Nuclear Medicine, 1988, 29(Suppl 1), 915. 36. Stafford-Schuck KA, Mountz JM, Foster NL, Ackermann RJ, Petry NA, Kuhl DE. Stroke prognosis using 99mTc- HM-PAO SPECT. Journal of Nuclear Medicine Technology, 1988, 16, A65.

×